专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150079173A1 FORMULATIONS DECREASING PARTICLE EXHALATION 审中-公开
标题翻译：制剂减少颗粒物排放
公开(公告)号：US20150079173A1
公开(公告)日：2015-03-19
申请号：US14058852
申请日：2013-10-21
申请人： PULMATRIX, INC.
发明人： David A. EDWARDS , Jonathan Chun-Wah MAN , Jeffrey P. KATSTRA , Robert W. CLARKE
IPC分类号： A61K47/02 , A61K9/00
CPC分类号： A61K47/02 , A61K9/0078 , A61K9/14 , A61K9/141 , A61K9/16 , A61M15/00
摘要： Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
摘要翻译：已经开发了用于肺部输送以治疗或降低人类感染病毒感染，特别是结核病，SARS，流感和呼吸道合成病毒以及动物蹄和口蹄疫等疾病或减轻过敏或其他肺部疾病症状的传染性的制剂疾病。用于肺部给药的制剂包括显着改变诸如等渗盐水和任选的载体的肺粘液衬里液体的表面张力和表面弹性的物理性质的材料。制剂可以作为液体溶液，悬浮液，气雾剂或粉末施用，其中颗粒基本上由渗透活性的溶质组成。药物，特别是抗病毒剂或抗生素，可以任选地包括在制剂中。这些可以与制剂一起施用或掺入制剂中。

2. 发明申请

US20150250875A1 DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES 有权
标题翻译：干粉配方及治疗肺炎的方法
公开(公告)号：US20150250875A1
公开(公告)日：2015-09-10
申请号：US14717243
申请日：2015-05-20
申请人： Pulmatrix, Inc.
发明人： Michael M. Lipp , Jean C. Sung , Robert W. Clarke , David L. Hava
IPC分类号： A61K47/02 , A61K31/137 , A61K47/18 , A61K9/00 , A61K47/12
CPC分类号： A61K47/02 , A61K9/0073 , A61K9/0075 , A61K31/137 , A61K31/198 , A61K33/06 , A61K33/14 , A61K47/12 , A61K47/183 , A61K2300/00 , A61M15/00 , B22F3/1125 , B22F5/10 , C22C21/00
摘要： The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.
摘要翻译：本发明涉及用于向呼吸道递送二价金属阳离子盐和/或一价阳离子盐的可呼吸干燥颗粒以及用于治疗患有呼吸道疾病和/或感染的受试者的方法。

3. 发明申请

US20150202227A1 RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE 审中-公开
标题翻译：包含氯酸钙，氯化钠和光亮剂的可呼吸干粉
公开(公告)号：US20150202227A1
公开(公告)日：2015-07-23
申请号：US14633432
申请日：2015-02-27
申请人： Pulmatrix, Inc.
发明人： Michael M. Lipp , Jean C. SUNG
IPC分类号： A61K33/06 , A61K47/18 , A61K45/06 , A61K31/56 , A61M15/00 , A61K31/46 , A61K31/5383 , A61K39/395 , A61K31/167 , A61K33/14 , A61K31/137
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K31/19 , A61K31/198 , A61K31/56 , A61K33/06 , A61K33/14 , A61K45/06 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to respirable dry powders that contain respirable dry particles that comprise calcium lactate, sodium chloride, leucine, and one or more additional therapeutic agents; wherein the ratio of calcium cation to sodium cation is about 4:1 (mole:mole); and, wherein the calcium lactate is about 45.0% (w/w) to about 58.6% (w/w), and the sodium chloride is about 1.9% (w/w) to about 3.9% (w/w), where all weights are on a dry basis.
摘要翻译：本发明涉及可吸入干粉，其包含可吸入的干颗粒，其包含乳酸钙，氯化钠，亮氨酸和一种或多种另外的治疗剂; 其中钙阳离子与钠阳离子的比例为约4:1（摩尔：摩尔）; 并且其中乳酸钙约为45.0％（w / w）至约58.6％（w / w），氯化钠为约1.9％（w / w）至约3.9％（w / w）重量是干的。

4. 发明申请

US20150004233A1 RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE 有权
标题翻译：包含氯酸钙，氯化钠和光亮剂的可呼吸干粉
公开(公告)号：US20150004233A1
公开(公告)日：2015-01-01
申请号：US14284880
申请日：2014-05-22
申请人： PULMATRIX, INC.
发明人： Michael M. LIPP , Jean C. SUNG
IPC分类号： A61K33/14 , A61K31/198 , A61K9/14 , A61K9/00 , A61M15/00 , A61K31/56 , A61K31/138 , A61K31/439 , A61K31/5383 , A61K31/137 , A61K33/06 , A61K45/06
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K31/19 , A61K31/198 , A61K31/56 , A61K33/06 , A61K33/14 , A61K45/06 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20%-37.5% (w/w) leucine, about 58.6-about 75% (w/w) calcium lactate, and about 3.9-about 5% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders.
摘要翻译：本发明涉及包含可吸入干颗粒的可呼吸干粉，其包含约20％-37.5％（w / w）亮氨酸，约58.6-约75％（w / w）乳酸钙和约3.9-约5％ w / w）氯化钠，以及使用可呼吸干燥粉末治疗受试者的方法。

5. 发明授权

US09737518B2 Tiotropium dry powders 有权
公开(公告)号：US09737518B2
公开(公告)日：2017-08-22
申请号：US14870736
申请日：2015-09-30
申请人： Pulmatrix, Inc.
发明人： Jean C. Sung , Diana Manzanedo , Jason M. Perry , Wesley Dehaan , Brian Trautman
IPC分类号： A61K31/05 , A61K31/4745 , A61K31/56 , A61K9/00 , A61K31/439 , A61K9/16 , A61K45/06 , A61K31/58 , A61K31/57
CPC分类号： A61K31/439 , A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K31/57 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： The present invention relates to respirable dry powder comprising respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is about 60% to about 90%, the leucine is about 10% to about 40%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is 67% to 84%, the leucine is 12% to 28%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise about 79.5% to about 80.5% (w/w) sodium chloride, about 19.5% to about 20.5% (w/w) leucine, and about 0.01% to about 0.5% (w/w) tiotropium bromide, and methods for treating a subject using the respirable dry powders.

6. 发明申请

US20150231066A1 MONOVALENT METAL CATION DRY POWDERS FOR INHALATION 审中-公开
标题翻译：单一金属粉末干燥粉末吸入
公开(公告)号：US20150231066A1
公开(公告)日：2015-08-20
申请号：US14666959
申请日：2015-03-24
申请人： Pulmatrix, Inc.
发明人： Michael M. Lipp , Jean C. Sung
IPC分类号： A61K9/00 , A61K47/18 , A61K31/56 , A61K31/439 , C07K16/00 , A61K38/28 , A61K31/5383 , A61K31/496 , A61K47/02 , A61K31/137
CPC分类号： A61K9/0073 , A61K9/0075 , A61K31/137 , A61K31/407 , A61K31/439 , A61K31/4745 , A61K31/496 , A61K31/5383 , A61K31/56 , A61K31/58 , A61K31/7036 , A61K38/00 , A61K38/28 , A61K39/00 , A61K39/395 , A61K47/02 , A61K47/183 , C07K16/00 , A61K2300/00
摘要： The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.
摘要翻译：本发明涉及可吸入干粉和用于全身递送药物活性剂或递送至呼吸道的颗粒。干粉含有一种或多种一价金属阳离子（如Na +），小而可分散。

7. 发明申请

US20140134251A1 PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS 审中-公开
标题翻译：药物制剂和治疗呼吸道感染的方法
公开(公告)号：US20140134251A1
公开(公告)日：2014-05-15
申请号：US14061006
申请日：2013-10-23
申请人： PULMATRIX, INC.
发明人： Michael M. LIPP , Robert W. CLARKE , David L. HAVA , Richard BATYCKY , John HANRAHAN
IPC分类号： A61K33/14 , A61K33/42 , A61K33/06 , A61K33/10 , A61K31/20 , A61K45/06 , A61K9/00 , A61K31/734 , A61K31/194 , A61K31/19 , A61K33/00 , A61K33/04
CPC分类号： A61K31/19 , A61K9/0078 , A61K31/194 , A61K31/20 , A61K31/734 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/10 , A61K33/14 , A61K33/42 , A61K45/06 , Y02A50/473 , Y02A50/478 , A61K2300/00
摘要： The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.
摘要翻译：本发明涉及用于治疗个体中的呼吸道感染或肺部疾病的药物制剂，其包含钙盐和钠盐，其中Ca + 2与Na +的比例为约4:1（摩尔：摩尔）至约16：1（摩尔：摩尔）。本发明还涉及治疗（包括预防性治疗）和减少呼吸道感染扩散的方法，治疗（包括预防性治疗）肺部疾病或肺部疾病急性加重的方法，以及减少是肺疾病的急性恶化，包括施用包含钙盐和钠盐的药物制剂。

8. 发明申请

US20160120855A1 TIOTROPIUM DRY POWDERS 有权
标题翻译：生物干粉
公开(公告)号：US20160120855A1
公开(公告)日：2016-05-05
申请号：US14870736
申请日：2015-09-30
申请人： Pulmatrix, Inc.
发明人： Jean C. Sung , Diana Manzanedo , Jason M. Perry , Wesley Dehaan , Brian Trautman
IPC分类号： A61K31/439 , A61K31/57 , A61K9/00
CPC分类号： A61K31/439 , A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K31/57 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： The present invention relates to respirable dry powder comprising respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is about 60% to about 90%, the leucine is about 10% to about 40%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise sodium chloride, leucine, and tiotropium bromide, wherein the sodium chloride is 67% to 84%, the leucine is 12% to 28%, the tiotropium bromide is about 0.01% to about 0.5%, and optionally one or more additional therapeutic agents up to about 20%, wherein all percentages are weight percentages on a dry basis and all the components of the respirable dry particles amount to 100%. The invention also relates to respirable dry powders that contain respirable dry particles that comprise about 79.5% to about 80.5% (w/w) sodium chloride, about 19.5% to about 20.5% (w/w) leucine, and about 0.01% to about 0.5% (w/w) tiotropium bromide, and methods for treating a subject using the respirable dry powders.
摘要翻译：本发明涉及包含氯化钠，亮氨酸和噻托溴铵的可吸入干颗粒的可呼吸干粉，其中氯化钠为约60％至约90％，亮氨酸为约10％至约40％，噻托溴铵约0.01％至约0.5％，以及任选的一种或多种另外的治疗剂至多约20％，其中所有百分比均为干基重量百分比，所有可呼吸干燥颗粒的组分均为100％。本发明还涉及含有可吸入干颗粒的可呼吸干燥粉末，其包含氯化钠，亮氨酸和噻托溴铵，其中氯化钠为67％至84％，亮氨酸为12％至28％，噻托溴铵为约0.01 ％至约0.5％，以及任选的一种或多种额外的治疗剂至多约20％，其中所有百分比均为干重的重量百分数，并且可呼吸干燥颗粒的所有组分均为100％。本发明还涉及可吸入干粉，其含有可吸入干颗粒，其包含约79.5％至约80.5％（w / w）氯化钠，约19.5％至约20.5％（w / w）亮氨酸，和约0.01％至约 0.5％（w / w）噻托溴铵，以及使用可呼吸干粉治疗受试者的方法。

9. 发明授权

US08992983B2 Respirably dry powder comprising calcium lactate, sodium chloride and leucine 有权
标题翻译：包含乳酸钙，氯化钠和亮氨酸的重要干燥粉末
公开(公告)号：US08992983B2
公开(公告)日：2015-03-31
申请号：US14284880
申请日：2014-05-22
申请人： Pulmatrix, Inc.
发明人： Michael M. Lipp , Jean C. Sung
IPC分类号： A61K33/14 , A61K33/06 , A61K31/198 , A61K9/14 , A61K9/00 , A61K45/06 , A61K31/56 , A61K31/138 , A61K31/5383 , A61K31/137 , A61M15/00 , A61K31/439
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K31/19 , A61K31/198 , A61K31/56 , A61K33/06 , A61K33/14 , A61K45/06 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20%-37.5% (w/w) leucine, about 58.6-about 75% (w/w) calcium lactate, and about 3.9-about 5% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders.
摘要翻译：本发明涉及包含可吸入干颗粒的可呼吸干粉，其包含约20％-37.5％（w / w）亮氨酸，约58.6-约75％（w / w）乳酸钙和约3.9-约5％ w / w）氯化钠，以及使用可呼吸干燥粉末治疗受试者的方法。

10. 发明申请

US20140336159A1 METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS 审中-公开
标题翻译：用于治疗和诊断呼吸道感染的方法
公开(公告)号：US20140336159A1
公开(公告)日：2014-11-13
申请号：US14350235
申请日：2012-10-05
申请人： PULMATRIX, INC.
发明人： Robert William Clarke , David L. Hava , John P. Hanrahan , Wesley Hugh Dehaan , Paulette Wright Andreotta , Stephen P. Arold , Jennifer Kenyon Saunders
IPC分类号： A61K31/19 , A61K9/00 , A61K31/56 , A61K45/06
CPC分类号： A61K31/19 , A61K9/0075 , A61K9/0078 , A61K31/56 , A61K33/06 , A61K33/10 , A61K33/14 , A61K45/06 , G01N33/6884 , G01N2500/10 , G01N2800/12 , G01N2800/52 , G01N2800/60
摘要： Described are methods of preventing, treating and diagnosing of a subject having a condition, such as, an inflammation or infection of the respiratory tract. Methods of treatment and prevention include administration of effective amounts of calcium salt formulations to a subject. Methods of diagnosing include the use of biomarkers and optionally the use of kits that can detect biomarkers. Further described are methods for modulating an immune response that include the modulation of Toll-like receptors.
摘要翻译：描述了预防，治疗和诊断具有诸如呼吸道炎症或感染等病症的对象的方法。治疗和预防方法包括向受试者施用有效量的钙盐制剂。诊断方法包括使用生物标志物和任选地使用可检测生物标志物的试剂盒。还描述了调节包括Toll样受体调节的免疫应答的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式